Urogynaecological symptoms are commonly encountered problems in women of post-reproductive age, which have a major impact on quality of life in affected women. This review summarises a standardised approach to common urogynaecological problems in primary care, which focuses on making the correct diagnosis, assessing impact, evaluating for other relevant lifestyle and medical factors and indications for referral into secondary care.
ZelekeBBellRBillahB, et al.
Symptomatic pelvic floor disorders in older community dwelling Australian women. Maturitas2016;
85: 34–41.
2.
KinchenSBurgioKDioknoA, et al.
Factors associated with women’s decisions to seek treatment for urinary incontinence. J Womens Health (Larchmt)2003;
12: 687–698.
3.
BasuMDuckettJ.Barriers to women seeking treatment for persistent or recurrent symptoms in urogynaecology. BJOG2009;
116: 726–730.
4.
National Institute for Health and Care Excellence (NICE). NG123: Urinary Incontinence and Pelvic Organ Prolapse in Women: Management.
London, UK:
NICE, 2019.
5.
HaylenBde RidderDFreemanR, et al.
An International Urogynecology Association (IUGA)/International Continence Society (ICS) joint report on the terminology for pelvic floor dysfunction. Neurourol Urodyn2010;
29: 4–20.
6.
RobinsonDHanna-MitchellARantellA, et al.
Are we justified in suggesting change to caffeine, alcohol and carbonated drink intake in lower urinary tract disease? Report from the ICI-RS 2015. Neurourol Urodyn2017;
4: 876–881.
7.
WelshTJvan der WardtVOjoG, et al.
Anticholinergic drug burden tools/scales and adverse outcomes in different clinical settings: a systematic review of reviews. Drugs Aging2018;
35: 523–538.
8.
MambattaAJayarajanJRashmeV, et al.
Reliability of dipstick assay in predicting urinary tract infection. J Family Med Prim Care2015;
4: 265–268.
9.
Jimenez-CidreMLopez FandoLEsteban-FuertesM, et al.
The 3-day bladder diary is a feasible, reliable and valid tool to evaluate the lower urinary tract symptoms in women. Neurourol Urodyn2015;
34: 128–132.
10.
BarberMMaherC.Epidemiology and outcome assessment of pelvic organ prolapse. Int Urogynecol J2013;
24: 1783–1790.
11.
CameronASmithALaiH, et al.
Bowel function, sexual function, and symptoms of pelvic organ prolapse in women with and without urinary incontinence. Neurourol Urodyn2018;
37: 2586–2596.
12.
GiriAHartmannKHellwegeJ, et al.
Obesity and pelvic organ prolapse: a systematic review and meta-analysis of observational studies. Am J Obstet Gynecol2017;
217: 11–26.
13.
WangCSymingtonJMaE, et al.
Estrogenic modulation of uropathogenic Escherichia coli infection pathogenesis in a murine menopause model. Infect Immun2013;
81: 733–739.
14.
PerrottaCAznarMMejiaR, et al.
Oestrogens for preventing recurrent urinary tract infection in postmenopausal women. Cochrane Datab Syst Rev2008;
16: CD005131.
15.
SathiananthamoorthySMalone-LeeJGillK, et al.
Reassessment of routine mid-stream urine culture in diagnosis of urinary tract infection. J Clin Microbiol2019;
57: e01452–18.
16.
National Institute for Health and Care Excellence. Urinary tract infection (recurrent): antimicrobial prescribing (NG112), www.nice.org.uk/ng112 (2018, accessed 8 June 2020).
